These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32085826)

  • 21. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of ezetimibe in the management of patients with atherosclerosis.
    Hamilton P
    Coron Artery Dis; 2009 Mar; 20(2):169-74. PubMed ID: 19106797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence.
    Mascitelli L; Pezzetta F; Goldstein MR
    Arch Med Res; 2010 Nov; 41(8):649-50. PubMed ID: 21199735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Concerning the significance of paraoxonase-1 and SR-B1 genes in atherosclerosis].
    Rodríguez Esparragón F; Hernández Trujillo Y; Macías Reyes A; Hernández Ortega E; Medina A; Rodríguez Pérez JC
    Rev Esp Cardiol; 2006 Feb; 59(2):154-64. PubMed ID: 16540037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ezetimibe on atherosclerosis in preclinical models.
    Davis HR; Lowe RS; Neff DR
    Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ursodeoxycholic acid on atherosclerosis.
    Ozturk K; Uygun A; Demirci H; Bagci S
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):865. PubMed ID: 26039180
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapy and clinical trials.
    Chandalia M; Jialal I
    Curr Opin Lipidol; 2005 Dec; 16(6):708-10. PubMed ID: 16276251
    [No Abstract]   [Full Text] [Related]  

  • 28. Atherosclerosis: cell biology and lipoproteins.
    Wahle KW; Heys SD
    Curr Opin Lipidol; 2008 Aug; 19(4):435-7. PubMed ID: 18607194
    [No Abstract]   [Full Text] [Related]  

  • 29. [The REVEAL study].
    Maggioni AP; Filardi PP
    G Ital Cardiol (Rome); 2018 Feb; 19(2):71-76. PubMed ID: 29531378
    [No Abstract]   [Full Text] [Related]  

  • 30. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
    Rosenson RS
    Am J Cardiol; 2007 Feb; 99(4A):96B-104B. PubMed ID: 17307062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholesterol and cost-effectiveness. Implications for practice, policy, and research.
    McBride PE; Davis JE
    Circulation; 1992 May; 85(5):1939-41. PubMed ID: 1572049
    [No Abstract]   [Full Text] [Related]  

  • 33. High-risk elderly patients PROSPER from cholesterol-lowering therapy.
    Collins R; Armitage J
    Lancet; 2002 Nov; 360(9346):1618-9. PubMed ID: 12457780
    [No Abstract]   [Full Text] [Related]  

  • 34. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.
    Hegele RA; Gidding SS; Ginsberg HN; McPherson R; Raal FJ; Rader DJ; Robinson JG; Welty FK
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2269-80. PubMed ID: 26376908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Considerable LDL lowering is advantageous].
    MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
    [No Abstract]   [Full Text] [Related]  

  • 37. Investigational therapies for hypercholesterolemia.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2017 May; 26(5):603-617. PubMed ID: 28368771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
    Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of lipid disorders in the elderly.
    Playford DA; Watts GF
    Drugs Aging; 1997 Jun; 10(6):444-62. PubMed ID: 9205850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CETP Inhibition in CVD Prevention: an Actual Appraisal.
    Di Bartolo B; Takata K; Duong M; Nicholls SJ
    Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.